Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsPaul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
Estimating the term…
The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
An isolated or purified nucleic acid comprising a nucleotide sequence encoding a T cell receptor (TCR) having antigenic specificity for MAGE-A12 presented by HLA-Cw7, wherein the TCR comprises the amino acid sequences of SEQ ID NOs:
An isolated or purified nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequences of SEQ ID NOs:
An isolated or purified nucleic acid comprising a nucleotide sequence encoding a protein, wherein the protein comprises:
Dependencies are inferred from the claim text.